Top Markets
Coin of the day
Oryzon Genomics S.A. Oryzon Genomics S.A.

Oryzon Genomics S.A.

ORY
Pozycja w akcjach #16839
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in... Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others. It also has collaborations in precision medicine with Columbia University in New York and the Institute of Medical and Molecular Genetics (INGEMM) at La Paz Hospital in Madrid psychometrically characterize patients with mutations in the SetD1A or Shank3 genes; and Cooperative Research and Development Agreement (CRADA) to sponsor several clinical trials. The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.
Cena akcji
$3.31
Ostatnia synchronizacja: 2026-09-01
Kapitalizacja rynkowa
$271.03M
Zmiana (1 dzień)
-0.36%
Zmiana (1 rok)
8.04%
Kraj
ES
Handel Oryzon Genomics S.A. (ORY)

Kategoria

Historia stopy dywidendy dla Oryzon Genomics S.A. (ORY)
Stopa dywidendy (TTM) dla Oryzon Genomics S.A. (symbol akcji: ORY) na dzień 2026 wynosi: 0
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla Oryzon Genomics S.A. (ORY) od 2026 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
Rok Stopa dywidendy Zmień
Za mało danych dla podanych dat.
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji